埃索美拉唑治疗消化性溃疡患者的临床效果观察

doi:10.3969/j.issn.1001-8131.2022.02.004

Abstract
Figure/Table
References
Related Citation (13)

Download: PDF (399 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective This study was aimed to investigate the clinical effects of esomeprazole in the treatment of peptic ulcer and influence on serum levels of inflammatory factors and gastrointestinal hormones.Methods 80 patients with peptic ulcer were enrolled in this study and randomly assigned to receive omegaprazole quadruple therapy（control group,40 cases）or esomeprazole quadruple therapy（observation group,40 cases）.Clinical effects of the two groups were compared.Meanwhile,serum inflammatory factors [interleukin-8（IL-8）,tumor necrosis factor-α（TNF-α）],gastrointestinal hormones [gastrin（GAS）,plasma motilin（MOT）,somatostatin（SS）],Hp clearance rate and drug safety were observed.Results After treatment,the total response rate in the observation group was 95.00%,higher than 87.50% in the control group（P>0.05）.After treatment,IL-8,TNF-α,GAS and MOT significantly decreased,while SS significantly increased in the 2 groups.Besides,IL-8,TNF-α,GAS and MOT were lower,and SS was significantly higher in the observation group than in the control group（P<0.05）.The Hp clearance rate was significantly higher in the observation group than in the control group after treatment（P<0.05）.No significant difference was found between the 2 groups in the total incidence of adverse drug reactions（P>0.05）.Conclusion The clinical effect of esomeprazole in the treatment of patients with peptic ulcer is definite.It has significant advantages in lower inflammatory factor levels and regulating serum gastrointestinal hormones.Besides,it can effectively improve the Hp clearance rate,with certain safety.

Key words： Peptic ulcer Esomeprazole Clinical effect Gastrointestinal hormone

Received: 02 February 2021

PACS:

R573.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Dongfang

Cite this article:

Wang Dongfang. Clinical Effect Observation of Esomeprazole in the Treatment of Peptic Ulcer[J]. journal1, 2022, 42(2): 11-13.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.02.004 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I2/11

[1] Reinau D,Schwenkglenks M.Glucocorticoids and the risk of peptic ulcer bleeding:case-control analysis based on swiss claims data[J].Drug Saf,2018,41(7):725-730.
[2] 周璐,刘永红.综合护理干预在根治消化性溃疡伴Hp感染患者中的应用[J].国际护理学杂志,2017,36(2):202-205.
[3] Venerito M,Schneider C,Costanzo R,et al.Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti inflammatory drugs,antiplatelet agents,anticoagulants,corticosteroids and selective serotonin reuptake inhibitors[J].Alimentary Pharmacology Therapeutics,2018,47(11):1464-1471.
[4] Ya W.Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication[J].World J Gastroenterol,2018,24(40):4596-4605.
[5] 车章洪,曾芳.埃索美拉唑四联疗法治疗Hp阳性消化性溃疡疗效及血清炎症因子的关联性研究[J].中国新药杂志,2018,27(12):1382-1386.
[6] 张声生,王垂杰,李玉锋,等.消化性溃疡中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,23(9):4089-4093.
[7] Anagnostopoulos GK,Tsiakos S,Margantinis G,et al.Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection:results of a randomized controlled study[J].Journal of Clinical Gastroenterology,2018,38(6):503-506.
[8] 宋东升,叶云,胥雄阳.埃索美拉唑四联方案治疗胃溃疡的临床疗效与患者的外周血T细胞亚群水平的关联性分析[J].现代免疫学,2018,38(1):25-30.
[9] 李常娟,张金华,魏俊伟,等.铋剂四联疗法联合双岐三联活菌对Hp感染患者的疗效[J].基因组学与应用生物学,2019,38(4):1939-1943.
[10] 管欣,李洪超,邵荣杰,等.奥美拉唑与埃索美拉唑三联疗法治疗消化性溃疡的系统综述与成本效果分析[J].中国医院药学杂志,2019,39(5):87-92.